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CY CLOSPORIN A (CsA) is an immunosuppresor drug that
has  been used in  the  treatment of  several  types  of
inflammatory diseases. In some of them the inhibi-
tion  of  T-lymphocyte  activation  does  not  suitably
account for the observed beneficial effect, suggesting
that CsA could act on other types of cells. The present
study was undertaken to determine the effect of CsA
on inflammatory cytokine secretion by U937 mono-
cyte  cells.  Undifferentiated  and  dimethylsulfoxide
(DMSO) differentiated U937 cells were incubated with
different concentrations of CsA (200, 20 and 2 ng/mL)
in  the  presence  or  absence  of  phorbol-myristate-
acetate (PMA). Interleukin-1b (IL-1b ), tumor necrosis
factor-a (TNF-a ), IL-6 and IL-8 levels were measured
in supernatants using specific enzyme-linked immu-
nosorbent assays. At the highest concentration used
(200 ng/mL) CsA decreased the basal and stimulated
secretion of all the inflammatory cytokines studied in
both  undifferentiated  and  differentiated  cells,  with
the only exception of PMA-stimulated IL-1 secretion
by undifferentiated cells. However, only basal secre-
tion  of  interleukin-8  in  both  undifferentiated  and
DMSO-differentiated  U937  cells  was  significantly
reduced by CsA at the highest concentration (200 ng/
mL). At therapeutic concentrations in vivo, CsA exerts
a  predominant  effect  on  IL-8  secretion  by  human
mononuclear phagocytes.
Key  words:  Cyclosporin,  Cytokine,  U937,  Macrophage,
Monocyte
Introduction
Cyclosporin A  (CsA)  is  an  immunomodulatory  sub-
stance used in the prevention of transplant rejection
and  in  the  treatment  of  autoimmune  diseases.1
Classically,  CsA  has  been  reported  to  exert  its
immunomodulatory  action  through  its  effect  on T
lymphocytes, mainly helper T lymphocytes, by inhibit-
ing calcineurin dependent interleukin (IL)-2 synthe-
sis.2,3 However,  it  has  been  suggested  that  the
inhibition of T lymphocyte activation by CsA does not
appropriately  account  for  all  the  effects  observed
following the in vivo administration of the drug.4 It is
possible that some effects could be due to the action
of CsA on other cells.5 It should be noted that CsA
binds to all human leucocytes. In fact, granulocytes
and cells of the mononuclear phagocyte system (MPS)
sometimes bind more CsA than lymphocytes, prob-
ably because the drug is rapidly internalized.2,6
Cells of  the MPS offer  an attractive possibility to
study the effects of this drug because they participate
in a crucial manner in antigen presentation and, in
many  cases,  are  the  final  effectors  of  the  immune
system. Many references in the literature report the
capacity of CsA to alter the activities of MPS cells. In
general,  the  capacities,  functions  and  actions  of
macrophages related to non-specific defense such as
chemotaxis, phagocytosis, enzyme release and respi-
ratory burst, are found to be more resistant to CsA.7,8
By  contrast,  those  related  to  immunoregulation  or
accessory functions, such as monokine production,
the  expression  of  histocompatibility  antigens  and
antigen  presentation,  are  more  susceptible  to  the
inhibitory action of CsA.7,8
Macrophages synthesize and secrete IL-1b, tumor
necrosis factor (TNF)-a, IL-6 and IL-8.9 These mono-
kines  are  known  mediators  of  the  inflammatory
response9 and are therefore also known as inflamma-
tory cytokines.
The aim of the present study was to evaluate the
effect of CsA on the secretion of IL-1b, TNF-a, IL-6 and
IL-8 by U937 monocyte-like cells.
Material and methods
Cell line
U937 cells were kindly supplied by Dr J. Olmos from
the  Hospital  Universitario  Marqu´ es  de  Valdecilla,
Santander (Spain). The cell line was kept at 37°C in a
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Mediators of Inflammation, 9, 169–174 (2000)humidified atmosphere with 5% CO2 in culture with
complete medium containing RPMI 1640  (Sigma®),
100U/mL of penicillin (Sigma®), 100U/mL of strepto-
mycine  (Sigma®),  2 mM  L-glutamine  (Sigma®)  and
10% fetal calf serum (FCS) (Gibco®) in sterile culture
flasks  (Nunclon®)  at  a  concentration  between
0.75´ 105 and  5´ 105 cells/mL.  Cell  viability  was
greater  than  90%  and  the  duplication  time  was
between  24  and  48  hours.  Cells  were  regularly
screened  for  lipopolysaccharide  (LPS),  bacteria,
mycoplasma and fungal contamination and found to
be negative. Cells were differentiated by incubation
over  4  days  in  complete  medium  containing  1.3%
(0.17M) dimethylsulfoxide (DMSO).
Cell cultures
5´ 105 cells together with different stimuli and/or CsA
at different concentrations were added to each well of
the culture dishes (Costar® 3513, 12 dishes 22.6mm
ø) with complete medium: Lipopolysaccharide from
E.  coli (Sigma®)  at  100mg/mL,  10mg/mL  and
1mg/mL;  phorbol-12-myristate-13-acetate  (PMA)
(Sigma®)  at  10 –4M,  10–5M  and  10–6M;  human
gamma-interferon (Sigma®) at 1000, 100 and 10U/mL
and  CsA  (Sandoz®)  at  three  non-toxic  in  vivo
concentrations: 200, 20 and 2ng/mL.
Cells were kept at 37°C in a humidified atmosphere
with 5% CO2 for 18h, after which supernatants were
centrifuged at 500g for 10min to sediment cells in
suspension and then stored at –70°C until assayed.
Cytokine determination
The  inflammatory  cytokines  were  determined  by
direct  double-sandwich  enzyme-linked  immunosor-
bent assay (ELISA)  in  the supernatants. BIOTRAK®
(Amersham, UK) commercial kits specific for human
IL-1b, TNF-a, IL-6 and IL-8 were used; these showed
no cross-reactivity with one another,  or with other
cytokines. They had a coefficient of variation less than
10%, and the following  respective sensitivity limits:
0.3pg/mL, 4.8pg/mL, 0.35pg/mL and 4.7pg/mL. All
samples  were  measured  in  duplicate.  Results  were
expressed in picograms/106 cells. None of the compo-
nents of the culture medium (RPMI 1640, antibiotics,
glutamine  or  fetal  calf  serum)  showed  immunor-
eactivity with the four types of cytokines studied.
Statistical analysis
All  data  are  expressed  as  means  ±  SEM.  For  each
cytokine t-test for paired data was used to compare
the  differences  in  cytokine secretion  between  CsA
treated  and  untreated  cells;  p values  <  0.05  were
considered significant.
Results
Differentiation of the U937 line
The data (not shown) confirming that suitable differ-
entiation  of  the  monocyte  cell  line  toward  macro-
phage cells had been achieved were as follows:
d A decrease in the cellular proliferation rate without
changing cell viability.
d An increase in adherence to the culture flasks and
among cells.
d An  increased  cytoplasm,  the  disappearance  of
nuclear polylobulation and a decrease in  nuclear
atypias and the number of nucleoli.
d An increase in the content of macrophage enzymes
(non-specific esterases).
d An increase in cytoplasmic RNA content.
Determination of type of stimulus and most
effective concentration on inflammatory
cytokine secretion
In order to study the most suitable type of stimulus for
inducing the secretion of inflammatory cytokines and
the  most  effective  concentration,  U937  cells  were
used under both differentiated and undifferentiated
conditions. Three classic stimuli were studied at three
different  concentrations:  lipopolysaccharide  (LPS),
phorbol  myristate  acetate  (PMA)  and  gamma-inter-
feron (g-IFN). The mean values of the results of the
study  carried out  in  duplicate  are  shown  for  each
cytokine in Fig. 1. Overall, the data obtained indicate
that the most potent stimulus of cytokine secretion
was PMA at a concentration of 10–5M.
Secretion of inflammatory cytokines by U937
cells
Once the required experimental conditions had been
established, inflammatory cytokine secretion by U937
cells was studied (Table 1). In basal conditions U937
cells secrete large amounts of IL-8, moderate amounts
of  IL-6  and TNF-a and  low  amounts  of  IL-1b. The
stimulation with PMA induces a large increase in the
secretion  of  all  cytokines.  Only  IL-6  secretion  was
stronger  in  differentiated  than  in  undifferentiated
cells.
Effect of CsA on inflammatory cytokine
secretion
The results on the effect of CsA on cytokine secretion
under both basal and stimulated conditions are shown
in Table 1. These data show the mean values obtained
in  four  different  assays.  At  therapeutic  in  vivo
concentrations (200mg/mL) CsA decreased basal and
stimulated secretion of all the inflammatory cytokines
studied  in  both  undifferentiated  and  differentiated
J. E. Losa Garcia et al.
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.cells, with the only exception being PMA-stimulated
IL-1 secretion by undifferentiated cells. However, only
basal  secretion  of  interleukin-8  in  both  undiffer-
entiated  and  DMSO-differentiated  U937  cells  was
significantly reduced by CsA at the highest concentra-
tion used (200ng/mL).
Effect of CsA on cell viability and cell
proliferation capacity
The inhibitory effect of CsA might be due to an effect
on cell viability and/or proliferation. Subsequently, a
duplicate study was performed in which the prolifera-
tion capacity and cell viability of U937 cells subjected
to the same stimuli as to those used in the study were
evaluated. As  shown in Table 2,  CsA did not affect
either  viability  or  proliferation  capacity,  either  in
undifferentiated U937 cells or in cells differentiated
with DMSO. Therefore the results on cytokine secre-
tion  cannot  be  interpreted  in  these  terms.  In  this
study,  the  effects  of  several  stimulatory  substances
were  also  assessed.  Both  PMA  and  LPS,  but  not
gamma-interferon,  were  shown  to  decrease  cell
viability.
Discussion
The  use  of  the U937  cell  line  in  the  evaluation  of
different  macrophage  functions  is  well  documen-
ted.10 This  human  cell  line  grows  continuously  in
suspension and was initially obtained from a pleural
effusion in a patient with histiocytic lymphoma.11 Its
phenotype corresponds to immature monocyte cells
arrested in a differentiation state close to the myelo-
monocytic  stem  cell.11 It  should  be  recalled  that
macrophages  are  highly  differentiated  cells  and
therefore have low proliferation capacity while cell
lines show a strong duplication rate. Thus, the first
step  in  our  work  was  to  differentiate  the  human
U937 monocyte cell line. In the presence of several
substances  U937  cells  undergo  a  process of  differ-
entiation  and  therefore  acquire  morphological  and
J. E. Losa Garcia et al.
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Table 1. Effect of CsA on basal and stimulated IL-1b, TNF-a, lL-6 and IL-8 secretion by U937 cells (pg/10
6 cells). The CsA
reduction of  inflammatory cytokine  secretion has stadistical  significance only in the case  of  basal IL-8 secretion in both
undifferentiated and differentiated cells. Data are expressed as mean ± SEM
IL-1 TNF-a IL-6 IL-8
Undifferentiated
Basal 5.3 ± 5.3 22.0 ± 11.7 38.4 ± 7.9 979.5 ± 281.4
+ CsA (2ng/mL) 10.8 ± 10.8 0.0 ± 0.0 37.6 ± 13.1 1596.7 ± 323.8
+ CsA (20ng/mL) 3.6 ± 3.6 8.4 ± 8.4 34.0 ± 12.7 1337.8 ± 343.9
+ CsA (200ng/mL) 0.5 ± 0.5 6.7 ± 6.7 25.2 ± 4.2 477.0 ± 185.6*
+PMA 10
5M 2717.1 ± 1733.1 5409.7 ± 4967.3 1705.1 ± 313.5 712,123.4 ± 48,360.1
+ CsA (200ng/mL) 2857.6 ± 1258.8 4727.8 ± 1427.8 731.4 ± 66.0 469,104.9 ± 109,861.8
DMSO differentiated
Basal 3.3 ± 3.3 17.8 ± 6.3 90.4 ± 27.6 948.8 ± 447.6
+CsA (2ng/mL) 3.1 ± 3.1 0.0 ± 0.0 99.7 ± 33.3 1732.8 ± 747.9
+CsA (20ng/mL) 1.1 ± 1.1 0.0 ± 0.0 91.4 ± 34.2 1452.6 ± 643.2
+CsA (200ng/mL) 2.6 ± 2.6 6.9 ± 6.1 67.1 ± 20.6 526.4 ± 342.6*
+ PMA 10
–5M 496.0 ± 136.2 4389.3 ± 3456.0 6343.7 ± 3135.6 446,567.3 ± 40,043.9
+CsA (200ng/mL) 144.0 ± 144.0 4372.5 ± 1717.6 2035.1 ± 1072.6 299,909.3 ± 43,399.6
*p<0.05 determined by t-test for paired data to compare cytokine secretion between CsA treated and untreated cells. Definition of abbreviations:
CsA, cyclosporin A; DMSO, dimethylsulfoxide; IL interleukin; PMA, phorbol myristate acetate; TNF-a, tumor necrosis factor alpha.
Table 2. Effect of CsA and of different stimuli on cell proliferation and viability. In this study we started out with a viable cell
concentration of 250,000 mL, obtaining the data after 18h of culture. CsA did not affect either the viability or proliferation
capacity of either differentiated or undifferentiated cells. Additionally, both LPS and PMA, but not interferon, decreased cell
viability
Undifferentiated U937 cell line
Viable cells/mL Viability (%)
Differentiated U937 cell line
Viable cells/mL Viability (%)
Basal conditions 370,000 91 317,000 95
PMA 10
–5M 240,000 84 128,000 76
LPS (100mg/mL) 335,000 88 280,000 88
g-interferon (1000U/mL) 400,000 94 285,000 92
CsA (200ng/mL) 385,000 94 300,000 93
CsA (200ng/mL) + PMA 10
–5M 240,000 77 115,000 81
Definition of abbreviations: CsA, cyclosporin A; LPS, lipopolysaccharide; PMA, phorbol myristate acetate.functional  characteristics similar to those of macro-
phages.12 Since one of  the interests of the present
work  was to assess the effect of  PMA on  cytokine
secretion,  DMSO  was  chosen  as  a  differentiating
agent because it displays differentiating capacity on
the  U937  cell  line.13 Differentiation  was  evaluated
by kinetic, morphological, cytochemical and molec-
ular  techniques. The  results  obtained,  which  were
similar  to  those  reported  by  other  authors,11,13
allowed  us  to  conclude  that  the  protocol  used  is
indeed  able  to  promote  the  differentiation  of  this
cell line.
DMSO-differentiated U937 cells retain their capac-
ity to be stimulated later on with different agents,13
among  them  PMA.14 It  should  be  noted  here  that
differentiation  and  activation  are  not  incompatible
concepts  and  that  it  is  in  fact  possible  to  employ
several  substances12 to  activate  cells  differentiated
with other agents. Here, we evaluated the effect of
three  known  macrophage  stimulating  agents  and
observed that for this purpose the most suitable agent
was  PMA  at  a  concentration  of  10–5M.  Although
according to  the literature  lower  concentrations of
this substance are usually  used,11,13 in each experi-
mental system it is necessary to obtain evidence of
the most effective concentration in the induction of a
given effect. In the present study the above concen-
tration was used. Although at this concentration PMA
directly decreases cellular viability, from a quantitative
point of view the increase that it induces in cytokine
secretion cannot be attributed to the elimination of
cytokines by dead cells.
The  cytokine  secretion  pattern  observed  under
both basal and PMA-stimulated conditions in this cell
line was similar to that of tissue macrophages such as
human  alveolar  macrophages.9,15 Different  studies
have  documented  the  production  of  inflammatory
cytokines  by  U937  cells  using  bioassays,16 immu-
noassays17–20 or  molecular  biology  techniques,16,19
although none of them used a protocol identical to
the  one  used  here.  From  the  quantitative  point  of
view,  the results obtained here are similar to those
reported by Hass et al. regarding IL1, TNF and IL-617
and  by  Bosco et  al.19 regarding  IL-8,  although  the
former authors17 did not detect IL-6 secretion, possi-
bly due to the stimulation conditions. By contrast, the
values described by Jiang et al.18 for IL-1, TNF and IL-6
and by Nishimura et al.21 for TNF are lower than our
own,  although  both  authors  also  used  different
protocols.  A  different  protocol  was  also  used  by
Srivastava  et  al.,20 who  reported  much  higher
amounts of  spontaneously secreted IL-8 in  compar-
ison with the present values. However, none of these
works  evaluated  the  release  of  the  four  cytokines
studied here jointly.
Only basal secretion of interleukin-8 in both undif-
ferentiated and DMSO-differentiated U937 cells was
significantly reduced by CsA at the highest concentra-
tion  used  (200ng/mL).  Our  group  has  previously
demonstrated  that  CsA  decreases  IL-8  secretion  in
human alveolar macrophages,22 however Mrowietz et
al. have  found  that  human  monocyte  interleukin-8
secretion  is  not  inhibited  by  CsA23 but  they  only
studied stimulated secretion and used higher and in
vivo toxic concentrations of CsA. The effect of CsA on
the U937 cell line is not well documented; in fact,
only  two  works  have  evaluated  the  action  of  this
immunomodulator on cytokine secretion.10,24 In this
sense, Tadmori et al.24 have shown that CsA decreases
TNF-a secretion in U937 cells, although these authors
used extremely  high  concentrations, and Keicho et
al.10 report the inhibitory effect of this immunomo-
dulator  on  IL-1a secretion.  In  these  two  works
incubations were higher than 24h.10,24
The  CsA  reduction  of  IL-8  secretion  by  human
macrophages is an interesting finding that may help to
explain the efficacy of CsA treatment in diseases like
psoriasis or pulmonary fibrosis in which neutrophilic
infiltration  is a key pathogenetic event.7,25,26 It has
been  demonstrated  that  CsA  inhibits  lymphocyte
chemotaxis27 and pulmonary recruitment of inflam-
matory leukocytes5 and that interleukin-8—a chem-
okine  that  recruits  and  activates  neutrophils—is  a
cyclosporin  A  binding  protein.28 Furthermore  the
cyclosporin  binding  proteins  or  cyclophilins  are
chemotactic  for  eosinophils  and  neutrophils29 and
their  chemotactic  activity  is  inhibited  by  CsA.29
Therefore it seems that CsA modulates chemotaxis.29
In  the opinion of  some authors, blocking  of chem-
otaxis may be the principal reason for the therapeutic
effect  of  cyclosporin  in  patients  with  diseases  like
psoriasis.30
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